

ARV Therapies and Therapeutic Strategies
INDEPENDENT REPORTING ON IAS 2017

**COMPREHENSIVE EXPERT REVIEW
AND DISCUSSION OF KEY PRESENTATIONS**

An Independent CME Activity Jointly Provided by Postgraduate Institute for Medicine and ViralEd, Inc.
This coverage is not sanctioned by the conference organizers and is not an official part of the conference proceedings.



WEEKLY ORAL MK-8591 PROTECTS MALE RHESUS MACAQUES AGAINST REPEATED LOW DOSE INTRARECTAL CHALLENGE WITH SHIVC109P3

M. Markowitz, A. Gettie, L. St. Bernard, H. Mohri, C.D. Andrews, A. Horowitz, J. Blanchard, B. Grasperge, L. Sun, K.L. Filigrove, D.J. Hazuda, J.A. Grobler

Abstract MOAX0203LB

SAFETY, TOLERABILITY AND PHARMACOKINETICS OF LONG-ACTING INJECTABLE CABOTEGRAVIR IN LOW-RISK HIV-UNINFECTED WOMEN AND MEN: HPTN 077

R. Landovitz, S. Li, B. Grinsztejn, H. Dawood, A. Liu, M. Magnus, M. Hosseinipour, R. Panchia, L. Cottle, G. Chau, P. Richardson, M. Marzinke, C. Hendrix, B. Tolley, A. Adeyeye, D. Burns, A. Rinehart, D. Margolis, M. McCauley, J. Eron

Abstract TUAC0106LB

MK-8591 (EFdA) GIVEN ONCE WEEKLY PROTECTIVE AGAINST SHIV CHALLENGE

Methods²

- MK-8591 (EFdA) is a long acting nucleoside reverse transcriptase translocation inhibitor – half life 168 hr
- Reduces HIV RNA levels by >1.5 log after a single dose in humans

10% Tween 5mL/kg With or Without MK-8591 3.9mg/kg by oral gavage (14 time points)

The timeline shows the study design. It starts at day 0 with 10% Tween 5mL/kg. At day 14, MK-8591 3.9mg/kg is administered orally. Subsequent doses are shown at days 2, 4, 6, 8, 10, 12, and 14. At day 16, the study enters the Washout/Follow-Up Phase. Red arrows indicate rectal challenges (50 TCID50SHIV; 12 Challenges) starting at day 2 and continuing every 2 weeks. Red double-headed arrows indicate blood collections starting at day 2 and continuing every 2 weeks. The timeline ends at day 24.


Results

A line graph showing aviremic (%) over 168 days. The Y-axis ranges from 0 to 100. The X-axis shows days from 0 to 168. The Placebo group (grey line) shows a rapid decline in aviremic percentage, reaching near zero by day 28. The MK-8591 group (blue line) maintains a high aviremic percentage (around 100%) throughout the 168-day period.


Grobler et al 2017 CROI, Seattle, WA 2. Markowitz M, et al. Matthews R, et al; 9th IAS, Paris, France, July 23-26, 2017; Abst. MOAX0203LB.

HPTN 077: SAFETY, TOLERABILITY, AND PK OF INJECTABLE CABOTEGRAVIR

Cohort 1:
30 mg po daily x 4 w
800 mg IM Q12W



Cohort 2:
30 mg po daily x 4 w
600 mg IM Q8W



Landovitz R, et al; 9th IAS, Paris, France, July 23-26, 2017; Abst. TUAC0106LB.